Erratum to spliceosome-associated protein 130: a novel biomarker for idiopathic pulmonary fibrosis.

[This corrects the article DOI: 10.21037/atm-20-4404.]. 2021 Annals of Translational Medicine. All rights reserved.

In the article titled “Spliceosome-associated protein 130: a novel biomarker for idiopathic pulmonary fibrosis” (1), corrections are needed due to carelessness on the part of the authors during the manuscript production process.

Page 2, the 1st sentence of the 4th paragraph in the “Introduction” section stated: “Spliceosome-associated protein 130 (SAP130), a subunit of histone deacetylase, is located in the nucleus in normal live cells but diffuses out of dying cells or damaged cells and is released to the extracellular milieu.” This sentence should be updated to: “Spliceosome-associated protein 130 (SAP130), also known as splicing factor 3B subunit 3 (SF3BP), a subunit of the splicing factor 3b protein complex, is located in the nucleus in normal live cells but diffuses out of dying or damaged cells and is released into the extracellular milieu.”

Page 3, the last sentence of “Immunohistochemistry (IHC)” in the “Methods” section stated: “Sections were deparaffinized and stained with Anti-SAP130 antibodies (ab 111739, Abcam) followed by biotinylated goat anti-mouse IgG and avidin-HRP.” However, the vendor information provided for SAP130 antibodies was incorrect: SAP130 antibodies were in fact purchased from Santa Cruz Biotechnologies under the catalogue number sc-398670. Therefore, the sentence should be updated to: “Sections were deparaffinized and stained with Anti-SAP130 antibodies (sc-398670, Santa Cruz Biotechnologies).”

The authors apologize for these errors, which did not affect the results or conclusion of the study.

Click here to view the updated version of the article.